Clinical Trials Insight: 700023726
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2008
At a glance
- Drugs Tetrahydrocannabivarin 9 (Primary)
- Indications Metabolic disorders; Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors GW Pharmaceuticals
- 22 Jan 2008 Status changed from initiated to completed.
- 12 Jun 2007 New trial record.